Latest News
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
More than 75 graduate students, postdoctoral fellows, and other early-career scientists from around the world participated in this year’s BrightFocus Alzheimer’s Fast Track, Nov. 9-11, 2022, in San Diego.
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
In this issue:
- President’s Corner
- Researcher Spotlight: Shannon Macauley, PhD
- Rare APOE Variant Reduces Plaques Linked to Alzheimer’s
- And more!
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.
BrightFocus Foundation yesterday presented its first-ever Alzheimer’s Disease Research (ADR) named awards to two leading researchers in recognition of their innovative work to prevent, treat, and, ultimately, cure Alzheimer’s disease.
Findings are the first to show a statistically significant decrease in cognitive decline by an anti-amyloid drug.
New BrightFocus-funded research explores how a protein called tau, critical to Alzheimer’s, turns from normal to a diseased state. This discovery presents a new target to potentially prevent or treat Alzheimer's disease.
Eye-brain research is revealing that the APOE4 mutation has a much different impact in glaucoma than in Alzheimer’s, a discovery that may lead to a new glaucoma treatment.
